Table 1

Demographics of study participants and baseline NFL

MS patients TREMEND
DMF
(±SD)
MS patients ADVANCE
placebo
(±SD)
Healthy controls
(±SD)
P value
Age (years)34.1 (±8.7)33.5 (±6.5)38.2 (±11.2)ns
Female/male (%)86.6%90%89.2%ns
Baseline CSF NFL (pg/mL)2368 (±1947)N/A416.8 (±191.2)P<0.0001
Baseline plasma NFL16.4 (±14.4)17.5 (±14.0)7.3 (±3.0)P<0.0001
  • TREMEND (Tecfidera in Relapsing-Remitting Multiple Sclerosis: Endothelial Dysfunction) (n=52) and ADVANCE (Pegylated interferon β−1a for relapsing-remitting multiple sclerosis) (n=48)18; mean±SD is shown. P values represent difference between healthy controls (n=23) versus patients in the ADVANCE and TREMEND trial, respectively. There was no significant difference between the ADVANCE and TREMEND trial.

  • CSF, cerebrospinal fluid; DMF, dimethyl fumarate; MS, multiple sclerosis; N/A, not available; NFL, neurofilament light; ns, not significant.